Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Recombinant Therapeutic Antibodies and Proteins market report explains the definition, types, applications, major countries, and major players of the Recombinant Therapeutic Antibodies and Proteins market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Biogen
Sanofi
Roche
Abbott
Pfizer
Eli Lilly
Merck
Novo Nordisk
Johnson and Johnson
Amgen
By Type:
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
By End-User:
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Recombinant Therapeutic Antibodies and Proteins Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Recombinant Therapeutic Antibodies and Proteins Outlook to 2028- Original Forecasts
-
2.2 Recombinant Therapeutic Antibodies and Proteins Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Recombinant Therapeutic Antibodies and Proteins Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Recombinant Therapeutic Antibodies and Proteins Market- Recent Developments
-
6.1 Recombinant Therapeutic Antibodies and Proteins Market News and Developments
-
6.2 Recombinant Therapeutic Antibodies and Proteins Market Deals Landscape
7 Recombinant Therapeutic Antibodies and Proteins Raw Materials and Cost Structure Analysis
-
7.1 Recombinant Therapeutic Antibodies and Proteins Key Raw Materials
-
7.2 Recombinant Therapeutic Antibodies and Proteins Price Trend of Key Raw Materials
-
7.3 Recombinant Therapeutic Antibodies and Proteins Key Suppliers of Raw Materials
-
7.4 Recombinant Therapeutic Antibodies and Proteins Market Concentration Rate of Raw Materials
-
7.5 Recombinant Therapeutic Antibodies and Proteins Cost Structure Analysis
-
7.5.1 Recombinant Therapeutic Antibodies and Proteins Raw Materials Analysis
-
7.5.2 Recombinant Therapeutic Antibodies and Proteins Labor Cost Analysis
-
7.5.3 Recombinant Therapeutic Antibodies and Proteins Manufacturing Expenses Analysis
8 Global Recombinant Therapeutic Antibodies and Proteins Import and Export Analysis (Top 10 Countries)
-
8.1 Global Recombinant Therapeutic Antibodies and Proteins Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Recombinant Therapeutic Antibodies and Proteins Export by Region (Top 10 Countries) (2017-2028)
9 Global Recombinant Therapeutic Antibodies and Proteins Market Outlook by Types and Applications to 2022
-
9.1 Global Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Plasma Protein Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Fusion Proteins Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Hormones Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Enzyme Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Coagulation Factors Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Hematology Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Immunology Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Endocrinology Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Infectious Disease Consumption and Growth Rate (2017-2022)
-
9.2.6 Global Cardiovascular Disease Consumption and Growth Rate (2017-2022)
-
9.2.7 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Recombinant Therapeutic Antibodies and Proteins Market Analysis and Outlook till 2022
-
10.1 Global Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.2.2 Canada Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.2.3 Mexico Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.2 UK Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.3 Spain Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.4 Belgium Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.5 France Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.6 Italy Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.7 Denmark Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.8 Finland Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.9 Norway Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.10 Sweden Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.11 Poland Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.12 Russia Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.3.13 Turkey Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.2 Japan Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.3 India Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.4 South Korea Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.5 Pakistan Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.6 Bangladesh Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.7 Indonesia Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.8 Thailand Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.9 Singapore Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.10 Malaysia Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.11 Philippines Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.4.12 Vietnam Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.5.2 Colombia Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.5.3 Chile Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.5.4 Argentina Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.5.5 Venezuela Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.5.6 Peru Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.5.7 Puerto Rico Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.5.8 Ecuador Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.6.2 Kuwait Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.6.3 Oman Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.6.4 Qatar Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.6.5 Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.6.6 United Arab Emirates Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.7.2 South Africa Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.7.3 Egypt Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.7.4 Algeria Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
-
10.8.2 New Zealand Recombinant Therapeutic Antibodies and Proteins Consumption (2017-2022)
11 Global Recombinant Therapeutic Antibodies and Proteins Competitive Analysis
-
11.1 Biogen
-
11.1.1 Biogen Company Details
-
11.1.2 Biogen Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Biogen Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.1.4 Biogen Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Sanofi
-
11.2.1 Sanofi Company Details
-
11.2.2 Sanofi Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.2.4 Sanofi Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Roche
-
11.3.1 Roche Company Details
-
11.3.2 Roche Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Roche Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.3.4 Roche Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Abbott
-
11.4.1 Abbott Company Details
-
11.4.2 Abbott Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Abbott Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.4.4 Abbott Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Pfizer
-
11.5.1 Pfizer Company Details
-
11.5.2 Pfizer Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.5.4 Pfizer Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Eli Lilly
-
11.6.1 Eli Lilly Company Details
-
11.6.2 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.6.4 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Merck
-
11.7.1 Merck Company Details
-
11.7.2 Merck Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.7.4 Merck Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Novo Nordisk
-
11.8.1 Novo Nordisk Company Details
-
11.8.2 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.8.4 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Johnson and Johnson
-
11.9.1 Johnson and Johnson Company Details
-
11.9.2 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.9.4 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Amgen
-
11.10.1 Amgen Company Details
-
11.10.2 Amgen Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Amgen Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
11.10.4 Amgen Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Recombinant Therapeutic Antibodies and Proteins Market Outlook by Types and Applications to 2028
-
12.1 Global Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Plasma Protein Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Fusion Proteins Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Hormones Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Enzyme Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Coagulation Factors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Hematology Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Immunology Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Endocrinology Consumption Forecast and Growth Rate (2022-2028)
-
12.2.5 Global Infectious Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.6 Global Cardiovascular Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.7 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Recombinant Therapeutic Antibodies and Proteins Market Analysis and Outlook to 2028
-
13.1 Global Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.2.2 Canada Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.2.3 Mexico Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.2 UK Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.3 Spain Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.4 Belgium Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.5 France Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.6 Italy Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.7 Denmark Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.8 Finland Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.9 Norway Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.10 Sweden Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.11 Poland Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.12 Russia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.3.13 Turkey Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.2 Japan Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.3 India Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.4 South Korea Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.8 Thailand Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.9 Singapore Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.11 Philippines Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.5.2 Colombia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.5.3 Chile Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.5.4 Argentina Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.5.6 Peru Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.6.3 Oman Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.6.4 Qatar Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.7.2 South Africa Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.7.3 Egypt Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.7.4 Algeria Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Recombinant Therapeutic Antibodies and Proteins Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Recombinant Therapeutic Antibodies and Proteins
-
Figure of Recombinant Therapeutic Antibodies and Proteins Picture
-
Table Global Recombinant Therapeutic Antibodies and Proteins Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Recombinant Therapeutic Antibodies and Proteins Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Plasma Protein Consumption and Growth Rate (2017-2022)
-
Figure Global Fusion Proteins Consumption and Growth Rate (2017-2022)
-
Figure Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)
-
Figure Global Hormones Consumption and Growth Rate (2017-2022)
-
Figure Global Enzyme Consumption and Growth Rate (2017-2022)
-
Figure Global Coagulation Factors Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Oncology Consumption and Growth Rate (2017-2022)
-
Figure Global Hematology Consumption and Growth Rate (2017-2022)
-
Figure Global Immunology Consumption and Growth Rate (2017-2022)
-
Figure Global Endocrinology Consumption and Growth Rate (2017-2022)
-
Figure Global Infectious Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Cardiovascular Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Recombinant Therapeutic Antibodies and Proteins Consumption by Country (2017-2022)
-
Table North America Recombinant Therapeutic Antibodies and Proteins Consumption by Country (2017-2022)
-
Figure United States Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Canada Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Mexico Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Table Europe Recombinant Therapeutic Antibodies and Proteins Consumption by Country (2017-2022)
-
Figure Germany Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure UK Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Spain Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Belgium Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure France Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Italy Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Denmark Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Finland Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Norway Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Sweden Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Poland Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Russia Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Turkey Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Table APAC Recombinant Therapeutic Antibodies and Proteins Consumption by Country (2017-2022)
-
Figure China Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Japan Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure India Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure South Korea Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Thailand Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Singapore Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Philippines Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Table South America Recombinant Therapeutic Antibodies and Proteins Consumption by Country (2017-2022)
-
Figure Brazil Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Colombia Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Chile Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Argentina Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Peru Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Table GCC Recombinant Therapeutic Antibodies and Proteins Consumption by Country (2017-2022)
-
Figure Bahrain Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Oman Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Qatar Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Table Africa Recombinant Therapeutic Antibodies and Proteins Consumption by Country (2017-2022)
-
Figure Nigeria Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure South Africa Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Egypt Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure Algeria Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Table Oceania Recombinant Therapeutic Antibodies and Proteins Consumption by Country (2017-2022)
-
Figure Australia Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Recombinant Therapeutic Antibodies and Proteins Consumption and Growth Rate (2017-2022)
-
Table Biogen Company Details
-
Table Biogen Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Biogen Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Sanofi Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Roche Company Details
-
Table Roche Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Roche Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Abbott Company Details
-
Table Abbott Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Abbott Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Pfizer Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Eli Lilly Company Details
-
Table Eli Lilly Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Merck Company Details
-
Table Merck Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Merck Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Novo Nordisk Company Details
-
Table Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Johnson and Johnson Company Details
-
Table Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Table Amgen Company Details
-
Table Amgen Recombinant Therapeutic Antibodies and Proteins Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Recombinant Therapeutic Antibodies and Proteins Main Business and Markets Served
-
Table Amgen Recombinant Therapeutic Antibodies and Proteins Product Portfolio
-
Figure Global Plasma Protein Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Fusion Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hormones Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Enzyme Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Coagulation Factors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hematology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Immunology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Endocrinology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Infectious Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Cardiovascular Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Recombinant Therapeutic Antibodies and Proteins Consumption Forecast by Country (2022-2028)
-
Table North America Recombinant Therapeutic Antibodies and Proteins Consumption Forecast by Country (2022-2028)
-
Figure United States Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Recombinant Therapeutic Antibodies and Proteins Consumption Forecast by Country (2022-2028)
-
Figure Germany Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Recombinant Therapeutic Antibodies and Proteins Consumption Forecast by Country (2022-2028)
-
Figure China Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Recombinant Therapeutic Antibodies and Proteins Consumption Forecast by Country (2022-2028)
-
Figure Brazil Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Recombinant Therapeutic Antibodies and Proteins Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Recombinant Therapeutic Antibodies and Proteins Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Recombinant Therapeutic Antibodies and Proteins Consumption Forecast by Country (2022-2028)
-
Figure Australia Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Recombinant Therapeutic Antibodies and Proteins Consumption Forecast and Growth Rate (2022-2028)
-
